急性缺血性卒中中内源性脱氧核糖核酸酶活性与游离脱氧核糖核酸:一项队列研究
本研究在汉诺威医学院前瞻性纳入92例因大血管闭塞接受机械取栓的卒中患者,于取栓前和7天后检测脱氧核糖核酸酶活性、游离DNA及炎性介质。调整混杂因素后,7天游离DNA与不良结局和死亡独立相关,基线脱氧核糖核酸酶活性较低与卒中相关感染相关,并在另一队列(n=92)中得到验证。
要点
- 大血管闭塞卒中取栓患者中,7天游离DNA独立与不良结局和死亡相关。
- 基线脱氧核糖核酸酶活性较低与卒中相关感染相关,调整后仍显著。
- 再灌注状态与游离DNA或脱氧核糖核酸酶活性无关联。
核心结论
- 内源性脱氧核糖核酸酶活性与游离DNA的相互作用为急性卒中提供了新的诊断和潜在治疗思路。
- 本研究证实游离DNA与大血管闭塞所致卒中后不良临床病程独立相关。
- 本研究首次提供证据表明较低的内源性脱氧核糖核酸酶活性是严重卒中后卒中相关感染的危险因素。
研究设计与样本
- 前瞻性队列研究,在汉诺威医学院于2018年3月至2019年8月招募92例因大血管闭塞接受机械取栓的卒中患者。
- 在机械取栓前即刻和7天后采集静脉血,检测脱氧核糖核酸酶活性、游离DNA、损伤相关分子模式和循环细胞因子。
- 再灌注状态分为充分/不充分,临床结局用90天改良Rankin量表评估,评分3至6分视为不良。
- 另设验证队列(n=92),在卒中发作后24小时内采血,用于验证卒中相关感染的发现。
主要发现
- 不良临床结局患者的游离DNA浓度更高。
- 调整混杂因素(Essen卒中风险评分、美国国立卫生研究院卒中量表评分和性别)后,7天游离DNA独立与临床结局相关(调整OR 3.485,95%CI 1.001-12.134),尤其与死亡率相关(调整OR 9.585,95%CI 2.006-45.790)。
- 再灌注状态与游离DNA或脱氧核糖核酸酶活性之间未发现关联。
- 游离DNA浓度与不同生物标志物正相关,而脱氧核糖核酸酶活性与不同生物标志物负相关。
- 发生卒中相关感染的患者基线脱氧核糖核酸酶活性低于未发生感染者,调整混杂因素后关联仍显著(调整OR 0.447,95%CI 0.237-0.844)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell-free DNA (cfDNA) and endogenous deoxyribonuclease activity are opposing mediators and might influence the inflammatory response following acute ischemic stroke. In this cohort study, we investigated the relation between these markers, circulating inflammatory mediators and clinical course including occurrence of stroke-associated infections (SAI) in patients with acute stroke. METHODS: Ninety-two patients with stroke due to large vessel occlusion undergoing mechanical thrombectomy were prospectively recruited at Hannover Medical School from March 2018 to August 2019. Deoxyribonuclease activity, cfDNA, damage-associated molecular patterns, and circulating cytokines were measured in venous blood collected immediately before mechanical thrombectomy and 7 days later. Reperfusion status was categorized (sufficient/insufficient). Clinical outcome was evaluated using the modified Rankin Scale after 90 days, where a score of 3 to 6 was considered unfavorable. To validate findings regarding SAI, another stroke cohort (n=92) was considered with blood taken within 24 hours after stroke onset. RESULTS: Patients with unfavorable clinical outcome had higher cfDNA concentrations. After adjustment for confounders (Essen Stroke Risk Score, National Institutes of Health Stroke Scale, and sex), 7-day cfDNA was independently associated with clinical outcome and especially mortality (adjusted odds ratio: 3.485 [95% CI, 1.001-12.134] and adjusted odds ratio: 9.585 [95% CI, 2.006-45.790]). No association was found between reperfusion status and cfDNA or deoxyribonuclease activity. While cfDNA concentrations correlated positively, deoxyribonuclease activity inversely correlated with distinct biomarkers. Baseline deoxyribonuclease activity was lower in patients who developed SAI compared with patients without SAI. This association was confirmed after adjustment for confounding factors (adjusted odds ratio: 0.447 [95% CI, 0.237-0.844]). In cohort 2, differences of deoxyribonuclease activity between patients with and without SAI tended to be higher with higher stroke severity. CONCLUSIONS: The interplay of endogenous deoxyribonuclease activity and cfDNA in acute stroke entails interesting novel diagnostic and potential therapeutic approaches. We confirm an independent association of cfDNA with a detrimental clinical course after stroke due to large vessel occlusion. This study provides first evidence for lower endogenous deoxyribonuclease activity as risk factor for SAI after severe stroke.
引用
- Grosse GM, Blume N, Abu-Fares O, et al. Endogenous Deoxyribonuclease Activity and Cell-Free Deoxyribonucleic Acid in Acute Ischemic Stroke: A Cohort Study. Stroke. 2022. PMID: 34991335. doi:10.1161/STROKEAHA.121.036299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。